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Background and PurposeᄏCilostazol, a phosphodiesterase III inhibitor, is known to be a 
useful antiplatelet agent that inhibits the progression of atherosclerosis in ischemic stroke. This 
study investigated the effects of combining cilostazol with aspirin on the expressions of P-selec-
tin and PAC-1 on activated platelets in acute ischemic stroke. 
MethodsᄏWe analyzed 70 patients with acute ischemic stroke (<72 hrs of an ischemic event). 
The daily intake was 100 mg of aspirin in 37 patients and 100 mg of aspirin plus 200 mg of 
cilostazol in 33 patients. The expressions of P-selectin and PAC-1 on activated platelets were 
measured on the day of admission and 5 days later. We also evaluated the clinical progression 
using the National Institutes of Health Stroke Scale (NIHSS) at the same times. 
ResultsᄏAfter 5 days the extent of PAC-1 expression on activated platelets was significantly 
lower for combined aspirin and cilostazol treatment (61.0±19.3%, p=0.008; mean±standard 
deviation) than the baseline level (70.9±12.9%), but did not differ between aspirin alone (66.0
±19.0%) and baseline (70.1±15.7%). The expression of P-selectin did not differ between 
combined aspirin and cilostazol treatment and baseline. The clinical progression did not differ 
between the two groups, as indicated by the absence of significant changes on the NIHSS in the 
acute period. 
ConclusionsᄏThis study found that the combined regimen of aspirin and cilostazol exerts the 
beneficial effect of reducing PAC-1 activity on activated platelets in acute ischemic stroke. 
However, the clinical outcome of this regimen was no better than that of the aspirin-only reg-
imen. Therefore, further detailed studies of the possible clinical benefits of cilostazol in acute 
ischemic stroke are needed.  J Clin Neurol 2008;4:148-152
 
Key Wordsᄏcilostazol, acute ischemic stroke. 
 
 
Introduction 
 
Platelet activation has been considered an important patho-
physiologic process in acute ischemic stroke,
1 which has led 
to antiplatelet agents being a very important therapeutic tool 
in curbing its progression.
2,3 Although there has been consid-
erable debate about the optimal medical therapy to apply in 
acute ischemic stroke, aspirin is still the most useful therapeu-
tic regimen for preventing its progression.
4,5 The beneficial 
effect of preventing the progression of intracranial stenosis 
was recently found to be greater for a combined aspirin and 
cilostazol regimen than for aspirin alone.
6 However, there 
are few data on the changes in platelet activation induced by 
cilostazol in acute ischemic stroke. 
In this study, we retrospectively analyzed the cilostazol-in-
duced changes in platelet activation in acute ischemic stroke. 
 
Methods 
 
We evaluated 440 patients with acute ischemic stroke (with-
in 72 hrs of an ischemic event) from November 2005 to De-
cember 2006. Platelet function assays were applied to 111 of 
the patients, and we selected 83 of these patients who had 
been prescribed aspirin alone (n=47) or aspirin plus cilosta-
zol (n=36). To improve the quality of our data, we excluded 
13 patients due to the presence of cardioembolism (n=4), in-
fection (n=4), and malignancy (n=5). We retrospectively 
investigated the types of ischemic stroke,
7 vascular risk fac- 
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tors, and changes in scores on the National Institutes of Health 
Stroke Scale (NIHSS) and the Modified Rankin Scale (mRS) 
at 30 days after ischemic stroke onset, and laboratory find-
ings including complete blood counts, a lipid battery, and C-
reactive protein (CRP).  
 
Measurement of platelet activation 
Peripheral venous blood was taken at two time points: be-
fore prescribing the medication and after 5 days of using it. 
The samples were anticoagulated with 3.2% sodium citrate. 
All patients or their relatives gave informed consent. 
The citrated whole blood samples were diluted sixfold in 
30 mL of HEPES buffer (137 mmol/L NaCl, 2.7 mmol/L KCl, 
20 mmol/L HEPES, 1 mg/mL bovine serum albumin, and 3.3 
mmol/L NaH2PO4; pH 7.4). Platelets were activated by add-
ing adenosine diphosphate at a final concentration of 100 μ M. 
The platelet population was detected using phycoerythrin 
(PE)-conjugated anti-CD42a (Pharmingen). Five milliliters 
of fluorescein isothiocyanate anti-P-selectin (Pharmingen) 
or PAC-1 monoclonal antibody (Pharmingen) was used for 
surface staining to detect the activated platelets. CD42a is 
present on both resting and activating platelets, while P-selec-
tin and PAC-1 were expressed only on activated platelets. 
After mixing and incubation for 15 min at room temperature, 
2.5 mL of HEPES buffer containing 0.2% formaldehyde was 
added. The stained platelets were analyzed by FACscan 
(EPICS XL, Coulter Electronics). The platelet-specific 
CD42a antigen was identified in 99% of the platelet pop-
ulation. After identifying positive fluorescence for the anti-
CD42a monoclonal antibody, the single-platelet popu-
lation was differentiated from microaggregates according 
to the degree of forward scatter. Microparticles were identi-
fied by positive fluorescence for PE-conjugated anti-CD42a 
and forward scatter below a size threshold of 0.5 mm. Anti-
body binding was expressed as the percentage of antibody-
positive platelets. We calculated the differences between 
unstimulated and stimulated platelets for each antibody. 
 
Results 
 
We finally reviewed the results of the platelet function assay 
in 70 patients with acute ischemic stroke (aspirin alone in 37 
patients, and combined aspirin and cilostazol in 33 patients). 
Patient characteristics, risk factors, and laboratory findings 
taken on the admission day are listed in Table 1. None of these 
parameters differed significantly between the two groups. 
The expressions of P-selectin and PAC-1 on activated 
platelets did not decrease during the observation period in the 
aspirin-only group. However, the expression of PAC-1 was 
significantly down-regulated after 7 days compared to the 
baseline in the aspirin plus cilostazol group (Figs. 1 and 2). 
CRP did not decrease significantly in either group during the 
Table 1. Comparison of clinical and laboratory findings between aspirin alone and aspirin plus cilostazol
  Aspirin alone  Aspirin plus cilostazol  p 
Number 37  33   
Men 25  22  0.938 
Age (yrs)  062.4±10.7  063.2±12.2 0.696 
Hypertension 30  (81.1)  022 (66.7) 0.244 
Diabetes mellitus  12 (32.4)  012 (36.4) 0.800 
Smoking 18  (48.6)  016 (48.5) 0.899 
Myocardial infarction  04  02 0.503 
Old cerebral infarction  02  02 0.884 
NIHSS score at baseline  005.2±3.6  005.8±4.6 0.136 
TOAST      
Atherosclerosis 24  (64.9) 25  (75.8) 0.362 
Small-vessel disease  13  08  
mRS score at baseline  002.1±1.0  002.2±1.1 0.849 
White blood cell count (×1,000/μL)  008.5±2.2  007.9±2.0 0.185 
Platelet count (×1,000/μL) 248.6±69.2 270.6±65.6 0.120 
Glucose (mg%) 175.6±81.2 173.7±110.4 0.913 
Total cholesterol (mg%) 205.7±40.9 214.1±77.2 0.335 
LDL cholesterol (mg%) 109.4±37.2 118.6±70.7 0.497 
Triglyceride (mg%) 124.4±81.7 144.5±111.7 0.292 
C-reactive protein (mg%)  00.42±1.00  00.60±1.83 0.590 
Data are number (percentage) or mean±standard deviation values. 
NIHSS: National Institutes of Health Stroke Scale, mRS: modified Rankin Scale, LDL: low-density lipoprotein, TOAST: Trial of ORG 10172 in 
Acute Stroke Treatment    
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observation period. The clinical improvement as measured 
by the NIHSS score did not differ significantly between the 
two groups (Fig. 3). 
 
Discussion 
 
Preventing early recurrence is the most important issue in the 
management of acute ischemic stroke.
8,9 The higher recur-
rence rate in atherosclerotic ischemic stroke than in other 
types of ischemic stroke
9 has been attributed to the progres-
sion of platelet activation, which has led to aspirin being a 
very important therapeutic strategy in acute ischemic stroke.
2 
However, the effects of aspirin might be too weak to curb plate-
let activation in acute ischemic stroke,
10 and there have been 
several trials of the effects of combined antiplatelet agents 
on preventing the recurrence of ischemic events in ischemic 
stroke.
11,12 In contrast to several successful trials using com-
bined antiplatelet agents in coronary syndrome,
13 many trials 
have failed to show the superiority of using two antiplatelet 
agents compared to using aspirin alone in ischemic stroke.
11,14 
Cilostazol is a type of phosphodiesterase inhibitor that both 
reduces platelet aggregation and enhances vascular dilatation.
15 
Several recent studies found that the progression of atheros-
clerosis was less for aspirin plus cilostazol than for aspirin 
alone,
6,16 particularly in intracranial atherothrombosis in 
transcranial Doppler and magnetic resonance angiography. 
These findings suggest that cilostazol provides advantages 
in curbing platelet activation in ischemic stroke.
6 However, 
there are few data supporting this hypothesis. 
This study evaluated whether aspirin plus cilostazol could 
reduce the expressions of P-selectin and PAC-1 on activated 
platelets in acute ischemic stroke. During platelet activation, 
the glycoprotein IIb/IIIa (GP IIb/IIIa) receptor changes into 
the activated form and connects with another activated plate-
lets via fibrinogen-bridging platelet aggregation.
17 PAC-1 
is a monoclonal antibody for detecting the activated GPIIb/IIIa 
receptor on activated platelets.
18 In the present study, aspi-
rin plus cilostazol significantly decreased the expression of 
PAC-1 on activated platelets in acute ischemic stroke, where-
as aspirin alone had no effect on PAC-1 expression. Although 
many previous studies have demonstrated that aspirin can 
efficiently block platelet aggregation within 30 min
19 the re-
ported positive results appeared only under certain experi-
mental conditions. Several stuies actually found that aspirin 
alone did not significantly regulate platelet activation or 
aggregation in atherothrombosis.
20,21 This could be due to 
platelet activation being enhanced by several other pathways 
in atherothrombosis, such as inflammatory reactions, free 
radical formation, and oxidized low-density lipoprotein.
22 
Therefore, the blocking of only one of several platelet acti-
vation pathways might not regulate platelet aggregation in 
atherothrombosis.  
It has previously been shown that aspirin plus cilostazol 
regulates PAC-1 expression on activated platelets in chronic 
atherothrombosis.
23 However, to the best of our knowledge, 
the present study is the first to show the usefulness of cilo-
stazol in reducing PAC-1 expression in ischemic stroke. 
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Fig. 3. Changes in mean NIHSS (National Institutes of Health 
Stroke Scale) scores. Vertical bars are standard deviations.  
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We found that P-selectin expression on activated platelets 
was not changed by cilostazol in acute ischemic stroke. P-
selectin is a transmembrane protein of the alpha-granules that 
becomes expressed on activated platelets.
17 Thereafter it in-
teracts with P-selectin glycoprotein ligand 1 (PSGL-1) on 
leukocytes, which then secrets cytokines and chemokines to 
aggravate the inflammatory processes, eventually increasing 
the atherosclerotic mass. However, few studies have shown 
that it is efficiently regulated by antiplatelet agents at usual 
doses in ischemic stroke. We considered that the expression 
of P-selectin on activated platelets would not be easily reg-
ulated by antiplatelet medication at usual doses. In line with 
our results, the Plavix Use for Treatment stroke trial
24 showed 
little changes in P-selectin expression on activated platelets 
in ischemic stroke when using the usual doses of aspirin alone 
or aspirin plus clopidogrel. 
We initially hypothesized that aspirin plus cilostazol curbs 
the inflammatory processes in acute ischemic stroke, but found 
that this was not the case. It is known that platelet activation 
reciprocally interacts with inflammatory processes in athero-
thrombosis.
25 Among several platelet activations, the expres-
sion of P-selectin on activated platelets might be intimately 
related with recruitment of inflammatory cells in atherogenic 
vessels. We therefore suggest that the small changes in the 
CRP level are due to the inability to reduce P-selectin expres-
sion on activated platelets for combined aspirin and cilostazol 
treatment. 
This study was subject to some limitations. First, it had a 
retrospective design, and there might have been an inhomo-
geneous distribution in the study population. Second, the study 
population was too small to predict the clinical benefit of cilo-
stazol in acute ischemic stroke. However, together the results 
from this study show the beneficial effect of aspirin plus cilo-
stazol in regulating platelet activation in acute ischemic stroke 
patients. 
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